Ethical Considerations Raised by Clinical Trials
Many of the ethical issues raised by clinical trials in multiple sclerosis (MS) are no different from those that arise in clinical research in other diseases. They are the basic ethical problems of the conduct of research on human subjects, more specifically, the problems of research on ill and vulnerable human subjects.
KeywordsMultiple Sclerosis Multiple Sclerosis Patient Safety Monitoring Committee Nuremberg Code Tuskegee Syphilis Study
Unable to display preview. Download preview PDF.
- Annas GJ, Grodin MA (1992) The Nazi doctors and the Nuremberg Code. Oxford University Press, New York, pp 102–103,331–342 xGoogle Scholar
- Clinical Research Subcommittee of the Scientific Issues Committee, American Academy of Neurology (1995) Status of clinical research in neurology. Neurology 45: 839–845Google Scholar
- Confavreaux C, Paty D (1995) Current status of computerization of multiple sclerosis clinical data for research in Europe and North America: the EDMUS/MS-COSTAR connection. Neurology 45: 573–576Google Scholar
- IFNB Multiple Sderosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661Google Scholar
- Kampmeier RH (1972) The Tuskegee study of untreated syphilis. South Med J 65:1247–1251 Kampmeier RH (1974) Final report on the “Tuskegee Syphilis Study”. South Med J 67:1349–1353 Katz J (1993) “Ethics and clinical research” revisited: a tribute to Henry K. Beecher. Hastings Cent Rep 23 (5): 31–39Google Scholar
- Munson R.(ed) (1992) Intervention and reflection: basic issues in medical ethics, 4th edn. Wadsworth, Belmont, CA, pp 392–394Google Scholar
- Spilker B (1991) Guide to clinical trials. Raven Press, New York, pp 124–128Google Scholar
- Wittes, J (1994) Monitoring clinical trials: relationships among data monitoring board, sponsor, and investigators [Abstract]. In: Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. A Meeting of the National Multiple Sclerosis Society; 1994 Feb; Charleston, SCGoogle Scholar